Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
作者信息
Rodríguez-Villodres Ángel, Ortiz de la Rosa José Manuel, Álvarez-Marín Rocío, Pachón Jerónimo, Aznar Javier, Lepe José Antonio, Smani Younes
机构信息
Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
Department of Medicine, University of Seville, Seville, Spain.
出版信息
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01923-17. Print 2018 Jan.
Abstract
摘要
相似文献
1
Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01923-17. Print 2018 Jan.
2
Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
Int J Antimicrob Agents. 2020 Apr;55(4):105919. doi: 10.1016/j.ijantimicag.2020.105919. Epub 2020 Feb 13.
3
Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
J Infect Chemother. 2015 May;21(5):381-4. doi: 10.1016/j.jiac.2015.01.006. Epub 2015 Jan 23.
4
Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
PLoS One. 2018 Jul 10;13(7):e0200442. doi: 10.1371/journal.pone.0200442. eCollection 2018.
5
Evaluation of Piperacillin-Tazobactam ETEST for the Detection of OXA-1 Resistance Mechanism among Escherichia coli and Klebsiella pneumoniae.
J Clin Microbiol. 2022 Dec 21;60(12):e0143022. doi: 10.1128/jcm.01430-22. Epub 2022 Nov 23.
6
Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Int J Antimicrob Agents. 2022 Apr;59(4):106543. doi: 10.1016/j.ijantimicag.2022.106543. Epub 2022 Feb 6.
7
Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.
J Antimicrob Chemother. 2020 Jan 1;75(1):77-85. doi: 10.1093/jac/dkz393.
8
Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.
J Antimicrob Chemother. 2019 Nov 1;74(11):3179-3183. doi: 10.1093/jac/dkz349.
9
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15.
10
Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
Microbiol Spectr. 2021 Oct 31;9(2):e0080121. doi: 10.1128/Spectrum.00801-21. Epub 2021 Oct 20.
引用本文的文献
1
Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study.
Lancet Microbe. 2025 Apr;6(4):101010. doi: 10.1016/j.lanmic.2024.101010. Epub 2025 Jan 16.
2
Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations.
Microbiol Spectr. 2023 Mar 6;11(2):e0336322. doi: 10.1128/spectrum.03363-22.
3
Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant by the MALDIpiptaz test.
Emerg Microbes Infect. 2022 Dec;11(1):2034-2044. doi: 10.1080/22221751.2022.2113746.
4
Phylogeny, Resistome, and Virulome of Causing Biliary Tract Infections.
J Clin Med. 2019 Dec 2;8(12):2118. doi: 10.3390/jcm8122118.
本文引用的文献
1
Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China.
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):571-8. doi: 10.1007/s10096-015-2572-x. Epub 2016 Jan 27.
2
Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China.
Clin Microbiol Infect. 2015 May;21(5):469.e1-10. doi: 10.1016/j.cmi.2014.12.013. Epub 2014 Dec 26.
3
Antimicrobial heteroresistance: an emerging field in need of clarity.
Clin Microbiol Rev. 2015 Jan;28(1):191-207. doi: 10.1128/CMR.00058-14.
4
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
J Antimicrob Chemother. 2008 Mar;61(3):757-8. doi: 10.1093/jac/dkm528. Epub 2008 Jan 15.
5
Sex and virulence in Escherichia coli: an evolutionary perspective.
Mol Microbiol. 2006 Jun;60(5):1136-51. doi: 10.1111/j.1365-2958.2006.05172.x.
6
Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals.
Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. doi: 10.1128/AAC.46.10.3156-3163.2002.
Zotero 插件